v2.3.0.11
Segment, Product and Geographic Area Information (Detail) (USD $)
In Millions
 3 Months Ended 6 Months Ended
Jul. 03, 2011
Jul. 04, 2010
Jul. 03, 2011
Jul. 04, 2010
Segment Reporting Information [Line Items]        
Revenues $ 16,984 $ 17,132 $ 33,486 $ 33,708
R&D Expenses 2,237 [1] 2,181 [1] 4,328 [1] 4,402 [1]
Earnings 3,682 [2] 3,926 [2] 6,800 [2] 7,075 [2]
Certain legal matters, net (14) [3] 37 [3] 487 [3] 174 [3]
Certain asset impairment charges 320 [4] 196 [4] 480 [4] 232 [4]
Other charges 25 (18) 29 (34)
Earnings [Member] | Certain significant items [Member]
        
Segment Reporting Information [Line Items]        
Restructuring charges and implementation costs associated with cost-reduction and productivity initiatives, excluding acquisition-related costs (256)   (828)  
Certain legal matters, net (53)   (525)  
Certain asset impairment charges (332) (200) (489) (200)
Other charges (17)   (24) (142)
Other Income   105   64
Certain significant items [Member]
        
Segment Reporting Information [Line Items]        
R&D Expenses 178 [5]   248 [5]  
Earnings (658) [2],[5] (95) [2],[5] (1,866) [2],[5] (278) [2],[5]
Primary Care [Member]
        
Segment Reporting Information [Line Items]        
Revenues 5,870 5,923 11,311 11,789
R&D Expenses 304 413 627 775
Earnings 3,811 [2] 4,054 [2] 7,357 [2] 8,137 [2]
Specialty Care And Oncology [Member]
        
Segment Reporting Information [Line Items]        
Revenues 4,038 4,118 8,276 8,002
R&D Expenses 375 377 722 741
Earnings 2,586 [2] 2,729 [2] 5,459 [2] 5,390 [2]
Established Products and Emerging Markets [Member]
        
Segment Reporting Information [Line Items]        
Revenues 4,732 4,980 9,277 9,736
R&D Expenses 79 65 135 97
Earnings 2,475 [2] 2,924 [2] 4,965 [2] 5,916 [2]
Animal Health and Consumer Healthcare [Member]
        
Segment Reporting Information [Line Items]        
Revenues 1,776 1,571 3,503 3,080
R&D Expenses 105 97 207 203
Earnings 514 [2] 482 [2] 1,003 [2] 879 [2]
Reportable Segments [Member]
        
Segment Reporting Information [Line Items]        
Revenues 16,416 16,592 32,367 32,607
R&D Expenses 863 952 1,691 1,816
Earnings 9,386 [2] 10,189 [2] 18,784 [2] 20,322 [2]
Nutrition and other business activities [Member]
        
Segment Reporting Information [Line Items]        
Revenues 568 [6] 540 [6] 1,119 [6] 1,101 [6]
R&D Expenses 868 [6] 849 [6] 1,724 [6] 1,769 [6]
Earnings (759) [2],[6] (728) [2],[6] (1,481) [2],[6] (1,521) [2],[6]
Corporate [Member]
        
Segment Reporting Information [Line Items]        
R&D Expenses 328 [7] 375 [7] 661 [7] 782 [7]
Earnings (1,647) [2],[7] (1,654) [2],[7] (3,307) [2],[7] (3,533) [2],[7]
Purchase Accounting Adjustments [Member]
        
Segment Reporting Information [Line Items]        
R&D Expenses   5 [8]   15 [8]
Earnings (1,736) [2],[8] (2,100) [2],[8] (3,521) [2],[8] (4,939) [2],[8]
Acquisition-related costs [Member]
        
Segment Reporting Information [Line Items]        
R&D Expenses     4 [9] 20 [9]
Earnings (595) [2],[9] (1,101) [2],[9] (1,170) [2],[9] (1,900) [2],[9]
Other unallocated [Member]
        
Segment Reporting Information [Line Items]        
Earnings $ (309) [10],[2] $ (585) [10],[2] $ (639) [10],[2] $ (1,076) [10],[2]
[1] Exclusive of amortization of intangible assets, except as disclosed in Note 11B. Goodwill and Other Intangible Assets: Other Intangible Assets.
[2] Income from continuing operations before provision for taxes on income.
[3] In the first six months of 2011, primarily relates to charges for hormone-replacement therapy litigation (see Note 14. Legal Proceedings and Contingencies).
[4] Substantially all of these asset impairment charges are related to intangible assets, including IPR&D assets, that were acquired as part of our acquisition of Wyeth. In the second quarter of 2011, impairment charges included approximately $200 million of IPR&D assets, primarily related to a single compound for the treatment of certain autoimmune and inflammatory diseases, and approximately $120 million of developed technology rights. In the first six months of 2011, impairment charges included approximately $360 million of IPR&D assets, primarily related to two compounds for the treatment of certain autoimmune and inflammatory diseases, and approximately $120 million of developed technology rights. In the second quarter and first six months of 2010, impairment charges of approximately $200 million related to certain IPR&D assets. The impairment charges are determined by comparing the estimated fair value of the assets as of the date of the impairment to their carrying values as of the same date. The impairment charges for all periods reflect, among other things, the impact of new scientific findings and updated commercial forecasts.
[5] Certain significant items are substantive, unusual items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition, the impact of certain tax and/or legal settlements and certain asset impairments. For the second quarter of 2011, certain significant items related to (a) R&D expenses, representing implementation costs and additional depreciation--asset restructuring associated with our cost-reduction and productivity initiatives that are not associated with an acquisition and (b) earnings, including: (i) restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition of $256 million, (ii) charges for certain legal matters of $53 million, (iii) certain asset impairment charges of $332 million and (iv) other charges of $17 million (see Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity and Note 6. Other (Income)/Deductions--Net for additional information). For the second quarter of 2010, certain significant items related to earnings included: (i) asset impairment charges of $200 million and (ii) other income of $105 million. For the first six months of 2011, certain significant items related to (a) R&D expenses, representing implementation costs and additional depreciation--asset restructuring associated with our cost-reduction and productivity initiatives that are not associated with an acquisition and (b) earnings, including: (i) restructuring charges and implementation costs associated with our cost-reduction and productivity initiatives that are not associated with an acquisition of $828 million, (ii) charges for certain legal matters of $525 million, (iii) certain asset impairment charges of $489 million and (iv) other charges of $24 million (see Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity and Note 6. Other (Income)/Deductions--Net for additional information). For the first six months of 2010, certain significant items included: (i) asset impairment charges of $200 million, (ii) charges for certain legal matters of $142 million, and (iii) other income of $64 million.
[6] Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the research and development costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.
[7] Corporate includes, among other things, administration expenses, interest income/(expense), certain performance-based and all share-based compensation expenses.
[8] Significant impacts of purchase accounting include charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.
[9] Acquisition-related costs can include costs associated with acquiring businesses and, integrating and restructuring acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring (see Note 5. Costs Associated with Cost-Reduction and Productivity Initiatives and Acquisition Activity for additional information).
[10] Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.